Kardigan registers Phase 3 open-label extension for danicamtiv in genetic DCM
The trial, "KINSHIP-OLE," was first posted August 18, 2026 to track long-term safety and efficacy in symptomatic genetic and familial dilated cardiomyopathy.
Kardigan, Inc. listed one new Phase 3 study this week covering its investigational drug danicamtiv.
- Kardigan registered NCT07771465, an open-label extension study titled "KINSHIP-OLE," first posted August 18, 2026 and listed as recruiting. Danicamtiv is described as an investigational medication that has not been approved, with the study designed to learn how well it works, how safe it is, and how well people can take it in patients with genetic or familial dilated cardiomyopathy (DCM).1 The record notes there are currently no approved medicines made specifically to treat genetic or familial DCM.1 The study is estimated to enroll 332 participants, with participants taking danicamtiv twice daily for up to 5 years and visiting the clinic about 16 times for clinical evaluations and diagnostic tests.1 Primary completion is estimated for November 2032.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.